| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
38,870,000 |
| Market
Cap: |
7.13(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1835 - $1.04 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Genprex is a clinical stage gene therapy company focusing on the development of gene-based therapies. Co.'s oncology platform utilizes its non-viral ONCOPREX™ Nanoparticle Delivery System. Co.'s primary oncology drug candidate, REQORSA™ Immunogene Therapy, also sometimes referred to as GPX-001, is being developed in combination with cancer drugs to treat Non-Small Cell Lung Cancer and Small Cell Lung Cancer. The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named TUSC2. In diabetes, Co. is developing a gene therapy that is licensed from the University of Pittsburgh of the Commonwealth System of Higher Education for the treatment of Type 1 and Type 2 diabetes.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
39,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$41,523 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Confer Ryan M. |
Chief Financial Officer |
• • – |
2024-02-18 |
4 |
D |
$4.40 |
$4,954 |
D/D |
(1,126) |
9,763 |
|
- |
|
| Berger Mark Stanley |
Chief Medical Officer |
• • – |
2024-02-18 |
4 |
D |
$4.40 |
$5,804 |
D/D |
(1,319) |
4,806 |
|
- |
|
| Varner John Rodney |
Chairman, President and CEO |
• • – |
2024-02-18 |
4 |
D |
$4.40 |
$11,625 |
D/D |
(2,642) |
26,352 |
|
- |
|
| Longnecker Brent M |
Director |
• • – |
2023-06-27 |
4 |
A |
$0.00 |
$0 |
D/D |
123,795 |
138,795 |
|
- |
|
| Moreno Toscano Jose Antonio |
Director |
• • – |
2023-06-27 |
4 |
A |
$0.00 |
$0 |
D/D |
123,795 |
123,795 |
|
- |
|
| Wilson William R Jr. |
Director |
• • – |
2023-06-27 |
4 |
A |
$0.00 |
$0 |
D/D |
123,795 |
123,795 |
|
- |
|
| Varner John Rodney |
Chairman, President and CEO |
• • – |
2023-04-21 |
4 |
B |
$1.06 |
$20,045 |
I/I |
19,000 |
20,800 |
2.58 |
-49% |
|
| Vaczy Catherine M |
EVP GC Chief Strategy Officer |
• • – |
2023-04-21 |
4 |
B |
$1.07 |
$21,478 |
D/D |
20,000 |
265,000 |
2.74 |
-49% |
|
| Berger Mark Stanley |
Chief Medical Officer |
• • – |
2023-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
245,000 |
245,000 |
|
- |
|
| Vaczy Catherine M |
EVP GC Chief Strategy Officer |
• • – |
2023-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
245,000 |
245,000 |
|
- |
|
| Confer Ryan M. |
Chief Financial Officer |
• • – |
2023-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
245,000 |
435,499 |
|
- |
|
| Varner John Rodney |
President & CEO |
• • – |
2023-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
625,000 |
1,159,735 |
|
- |
|
| Kumar Hermant |
Chief Mfgr & Tech Officer |
• • – |
2023-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
200,000 |
|
- |
|
| Confer Ryan M. |
Chief Financial Officer |
• • – |
2022-07-28 |
4 |
OE |
$0.02 |
$1,755 |
D/D |
116,973 |
190,499 |
|
- |
|
| Longnecker Brent M |
Director |
• • – |
2021-04-05 |
4 |
B |
$4.15 |
$62,250 |
D/D |
15,000 |
15,000 |
2.39 |
-31% |
|
| Longnecker Brent M |
Director |
– • – |
2020-03-18 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
20,000 |
|
- |
|
| Varner John Rodney |
Chief Executive Officer |
• • • |
2019-09-05 |
4 |
B |
$0.89 |
$1,595 |
I/I |
1,800 |
1,800 |
2.56 |
- |
|
| Ly Viet-An Hoan |
10% Owner |
– – • |
2018-09-27 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,160,982) |
36,067 |
|
- |
|
| Pham Julien L |
President & COO |
• – – |
2018-07-30 |
4 |
B |
$3.40 |
$1,700 |
D/D |
500 |
500 |
2.66 |
- |
|
| Varner John Rodney |
Chief Executive Officer |
• • • |
2018-03-29 |
4 |
B |
$5.00 |
$50,000 |
D/D |
10,000 |
544,735 |
3.23 |
- |
|
| Roth Jack A |
10% Owner |
– – • |
2018-03-29 |
4 |
B |
$5.00 |
$200,000 |
I/I |
40,000 |
1,338,999 |
1.5 |
- |
|
| Nance Christy M. |
10% Owner |
– – • |
2018-03-29 |
4 |
B |
$5.00 |
$250,000 |
D/D |
50,000 |
50,000 |
2.45 |
- |
|
22 Records found
|
1
|
Page 1 of 1 |
|
|
